{"id":8022,"date":"2022-06-19T18:47:02","date_gmt":"2022-06-20T02:47:02","guid":{"rendered":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=8022"},"modified":"2023-05-10T18:07:56","modified_gmt":"2023-05-11T02:07:56","slug":"risankizumab-skyrizi-receives-fda-approval-as-the-first-and-only-specific-interleukin-23-il-23-to-treat-moderately-to-severely-active-crohns-disease-in-adults","status":"publish","type":"post","link":"https:\/\/store.apotheraspecialtypharmacy.com\/?p=8022","title":{"rendered":"Risankizumab (SKYRIZI) Receives FDA Approval as the First and Only Specific Interleukin-23 (IL-23) to Treat Moderately to Severely Active Crohn’s Disease in Adults"},"content":{"rendered":"

Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely active Crohn’s disease, ADVANCE, MOTIVATE and FORTIFY
\n<\/em><\/p>\n

– As early as week 4 in the induction studies, clinical response and clinical remission were achieved by significantly more subjects treated with SKYRIZI versus placebo, as were co-primary endpoints of endoscopic response and clinical remission at week 12<\/em><\/p>\n

– Crohn’s disease is chronic, systemic and progressive; most patients experience unpredictable symptoms that have a significant impact on daily<\/em><\/p>\n

AbbVie today announced that the U.S. Food and Drug Administration (FDA) has approved SKYRIZI\u00ae (risankizumab-rzaa) as the first and only specific interleukin-23 (IL-23) inhibitor for the treatment of adults with moderately to severely active Crohn’s disease (CD).4 In two induction and one maintenance clinical trials, SKYRIZI demonstrated significant improvements in endoscopic response (defined as a decrease of greater than 50% from the baseline Simple Endoscopic Score in CD [SES-CD] or for patients with isolated ileal disease and SES-CD of 4, at least a 2-point reduction from baseline) and clinical remission (defined as a Crohn’s Disease Activity Index [CDAI] of less than 150), compared to placebo, as both an induction and maintenance therapy.<\/p>\n

The dosing regimen for SKYRIZI for the treatment of CD is 600 mg administered by intravenous infusion over at least one hour at week 0, week 4, and week 8, followed by 360 mg self-administered by subcutaneous injection (SC) with an on-body injector (OBI) at week 12, and every 8 weeks thereafter. A 180 mg self-administered SC maintenance dose option remains under review by the FDA.<\/p>\n

Endoscopic and Clinical Outcomes<\/strong>
\nThe co-primary endpoints of the clinical trials were endoscopic response and clinical remission. In the 12-week induction studies, ADVANCE and MOTIVATE, a significantly greater proportion of patients treated with SKYRIZI achieved endoscopic response and clinical remission compared to placebo. As early as week 4, clinical response (defined as a 100-point reduction in CDAI) and clinical remission were achieved in a significantly greater proportion of patients receiving SKYRIZI as compared to placebo.<\/p>\n

In the 52-week maintenance trial, FORTIFY, a significantly greater proportion of patients achieved the co-primary endpoints of endoscopic response and clinical remission as compared with the placebo group (risankizumab induction responders) after one year.<\/p>\n

Safety
\nSKYRIZI may cause serious side effects, including:<\/strong><\/p>\n